See what’s new.
Vega Health Launches to Deliver on AI’s Promise in Healthcare
Backed by Bessemer Venture Partners, Vega Health raises $4 million to connect health systems with AI solutions through curated marketplace, proprietary integration platform, and objective monitoring to maximize value
Duke Inventions Return a Record $115M Revenue in FY25, Highlighting Momentum in Research Translation
OTC reports highest-ever revenue as invention disclosures rise, while Duke Capital Partners delivers its strongest investment year ever.
Uplinza® (inebilizumab-cdon) is Now the First and Only FDA-Approved Treatment for IgG4-Related Disease
Originally developed at Duke, Amgen’s UPLIZNA® secures FDA approval as the first treatment for IgG4-related disease, achieving an 87% reduction in flare risk through CD19+ B-cell targeting.
Fellow Turned Inventor Gives Glaucoma Care an Upgrade
While Gabriel and Challa iterated on the new and improved GDD, they also tapped into Duke’s innovation ecosystem resources and connected with Duke’s Office for Translation & Commercialization (OTC), Duke’s tech transfer office.
Colleagues off the Court: Duke and UNC Champion Research and Innovation on Capitol Hill
From Google’s search to 3D printing, from MRIs to mRNA vaccines, countless products and services that make our lives better started as university born innovations from research.
Donald Patrick McDonnell, PhD, Wins 2025 Baxter Prize for Entrepreneurship
Professor Donald McDonnell (PCB, SOM) is a serial inventor with multiple commercialized technologies, including FDA-approved breast cancer drug ORSERDU.
Tune Therapeutics Names John McHutchison as CEO and Chairman of the Board
New Tune CEO John McHutchison has held professorships and associate directorships at SOM and DCRI. Tune is a Duke spinout and DCP portfolio company.
Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform
Tavros Therapeutics was co-founded by Eoin McDonnell, graduate of the Duke University Molecular Cancer Biology PhD Program, and Associate Professor Kris Wood (Pharmacology and Cancer Biology, SOM).
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
Humacyte is a Duke University start-up out of the lab of Dr. Laura Niklason (formerly Anesthesiology, SOM), co-founded with Drs. Juliana Blum and Shannon Dahl.